Literature DB >> 10638943

Biochemical differentiation of the porphyrias.

J T Hindmarsh1, L Oliveras, D C Greenway.   

Abstract

OBJECTIVES: To differentiate the porphyrias by clinical and biochemical methods. DESIGN AND METHODS: We describe levels of blood, urine, and fecal porphyrins and their precursors in the porphyrias and present an algorithm for their biochemical differentiation. Diagnoses were established using clinical and biochemical data. Porphyrin analyses were performed by high performance liquid chromatography. RESULTS AND
CONCLUSIONS: Plasma and urine porphyrin patterns were useful for diagnosis of porphyria cutanea tarda, but not the acute porphyrias. Erythropoietic protoporphyria was confirmed by erythrocyte protoporphyrin assay and erythrocyte fluorescence. Acute intermittent porphyria was diagnosed by increases in urine delta-aminolevulinic acid and porphobilinogen and confirmed by reduced erythrocyte porphobilinogen deaminase activity and normal or near-normal stool porphyrins. Variegate porphyria and hereditary coproporphyria were diagnosed by their characteristic stool porphyrin patterns. This appears to be the most convenient diagnostic approach until molecular abnormalities become more extensively defined and more widely available.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10638943     DOI: 10.1016/s0009-9120(99)00067-3

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  8 in total

1.  Feline porphyria associated with anemia, severe hepatic disease, and renal calculi.

Authors:  Jonathan J Schnier; Paul Hanna
Journal:  Can Vet J       Date:  2010-10       Impact factor: 1.008

Review 2.  Porphyrias at a glance: diagnosis and treatment.

Authors:  Maria Domenica Cappellini; Valentina Brancaleoni; Giovanna Graziadei; Dario Tavazzi; Elena Di Pierro
Journal:  Intern Emerg Med       Date:  2010-10       Impact factor: 3.397

3.  Genetic and biochemical characterization of 16 acute intermittent porphyria cases with a high prevalence of the R173W mutation.

Authors:  J To-Figueras; C Badenas; C Carrera; C Muñoz; M Milá; M Lecha; C Herrero
Journal:  J Inherit Metab Dis       Date:  2006-08       Impact factor: 4.982

4.  Harderoporphyria due to homozygosity for coproporphyrinogen oxidase missense mutation H327R.

Authors:  Alev Hasanoglu; Manisha Balwani; Ciğdem S Kasapkara; Fatih S Ezgü; Ilyas Okur; Leyla Tümer; Alpay Cakmak; Irina Nazarenko; Chunli Yu; Sonia Clavero; David F Bishop; Robert J Desnick
Journal:  J Inherit Metab Dis       Date:  2010-11-20       Impact factor: 4.982

5.  A LC-MS/MS method for the specific, sensitive, and simultaneous quantification of 5-aminolevulinic acid and porphobilinogen.

Authors:  Jinglan Zhang; Makiko Yasuda; Robert J Desnick; Manisha Balwani; David Bishop; Chunli Yu
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2011-07-06       Impact factor: 3.205

6.  Porphyrins are increased in the faeces of patients with prostate cancer: a case-control study.

Authors:  Daniel Riani Gotardelo; Lilia Coronato Courrol; Maria Helena Bellini; Flávia Rodrigues de Oliveira Silva; Carlos Roberto Jorge Soares
Journal:  BMC Cancer       Date:  2018-11-12       Impact factor: 4.430

7.  Clinical manifestations and diagnostic challenges in acute porphyrias.

Authors:  Henry Trier; Vikram P Krishnasamy; Pashtoon Murtaza Kasi
Journal:  Case Rep Hematol       Date:  2013-02-12

8.  A study of concentration changes of Protoporphyrin IX and Coproporphyrin III in mixed samples mimicking conditions inside cancer cells for Photodynamic Therapy.

Authors:  Rainer Landes; Alfredo Illanes; Daniela Goeppner; Harald Gollnick; Michael Friebe
Journal:  PLoS One       Date:  2018-08-31       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.